AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518 IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Acute Lymphoblastic Leukaemia [all]
  • Age: Between 1 - 21 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Patients must have B-Acute Lymphoblastic Leukemia (B-ALL) 2. Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy

You may not be eligible for this study if the following are true:

  • 1. Patients with any prior history of SOS/VOD irrespective of severity 2. Patients with isolated CNS, testicular, or other extramedullary site of relapse. 3. Patients who have been previously treated with InO.


If you are registered as a volunteer, please login to the dashboard to send referrals.